published meta-analysis   sensitivity analysis   studies

convalescent plasma treatment in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsSekine (PLACOVID), 2021 2.14 [0.70; 6.58] 2.14[0.70; 6.58]Sekine (PLACOVID), 202110%160NAnot evaluable death D28detailed resultsAlQahtani, 2020 0.47 [0.04; 5.69] Li, 2020 0.59 [0.22; 1.59] O’Donnell, 2021 0.47 [0.21; 1.06] PlasmAr, 2020 0.93 [0.47; 1.85] Pouladzadeh, 2021 0.31 [0.01; 10.20] RECOVER, 2021 1.09 [0.38; 3.13] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] 0.86[0.61; 1.22]AlQahtani, 2020, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, RECOVER, 2021, Sekine (PLACOVID), 202170%1,007lownot evaluable deathsdetailed resultsAlQahtani, 2020 0.47 [0.04; 5.69] CAPSID, 2021 0.84 [0.28; 2.50] CP-COVID-19, 2021 3.20 [0.62; 16.39] Li, 2020 0.59 [0.22; 1.59] O’Donnell, 2021 0.47 [0.21; 1.06] PlasmAr, 2020 0.93 [0.47; 1.85] Pouladzadeh, 2021 0.31 [0.01; 10.20] Rasheed, 2020 0.13 [0.01; 1.09] RECOVER, 2021 1.09 [0.38; 3.13] REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] 0.91[0.71; 1.15]AlQahtani, 2020, CAPSID, 2021, CP-COVID-19, 2021, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Rasheed, 2020, RECOVER, 2021, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 20211112%3,241lowlow deaths (time to event analysis only)detailed resultsCP-COVID-19, 2021 3.20 [0.62; 16.39] PlasmAr, 2020 0.93 [0.47; 1.85] 1.37[0.45; 4.21]CP-COVID-19, 2021, PlasmAr, 2020246%434lownot evaluable clinical deteriorationdetailed resultsCAPSID, 2021 0.63 [0.29; 1.40] 0.63[0.29; 1.40]CAPSID, 202110%105NAnot evaluable clinical improvementdetailed resultsCAPSID, 2021 1.58 [0.71; 3.49] Li, 2020 1.40 [0.79; 2.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 0.81 [0.50; 1.31] Pouladzadeh, 2021 7.31 [1.62; 32.97] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] 1.16[0.87; 1.56]CAPSID, 2021, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Sekine (PLACOVID), 2021654%984moderateserious clinical improvement (14-day)detailed resultsLi, 2020 2.27 [0.90; 5.72] 2.27[0.90; 5.72]Li, 202010%103NAnot evaluable clinical improvement (28-day)detailed resultsLi, 2020 1.42 [0.65; 3.10] O’Donnell, 2021 1.38 [0.73; 2.61] Pouladzadeh, 2021 7.31 [1.62; 32.97] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] 1.41[0.82; 2.45]Li, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021465%546moderatenot evaluable clinical improvement (7-day)detailed resultsLi, 2020 0.98 [0.27; 3.58] 0.98[0.27; 3.58]Li, 202010%103NAnot evaluable clinical improvement (time to event analysis only)detailed resultsLi, 2020 1.40 [0.79; 2.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 1.00 [0.76; 1.32] 1.12[0.92; 1.36]Li, 2020, O’Donnell, 2021, PlasmAr, 202030%660lownot evaluable mechanical ventilationdetailed resultsAlQahtani, 2020 0.67 [0.22; 2.02] O’Donnell, 2021 1.50 [0.47; 4.82] PlasmAr, 2020 0.86 [0.39; 1.93] 0.92[0.52; 1.62]AlQahtani, 2020, O’Donnell, 2021, PlasmAr, 202030%596lownot evaluable mechanical ventilation (time to event analysis only)detailed resultsCP-COVID-19, 2021 0.66 [0.25; 1.72] 0.66[0.25; 1.72]CP-COVID-19, 202110%100NAnot evaluable viral clearance detailed resultsCP-COVID-19, 2021 1.12 [0.16; 7.84] 1.12[0.16; 7.84]CP-COVID-19, 202110%100NAnot evaluable viral clearance by day 14detailed resultsCP-COVID-19, 2021 1.51 [0.33; 6.94] 1.51[0.33; 6.94]CP-COVID-19, 202110%100NAnot evaluable ICU admissiondetailed resultsCP-COVID-19, 2021 0.82 [0.35; 1.91] 0.82[0.35; 1.91]CP-COVID-19, 202110%100NAnot evaluable serious adverse eventsdetailed resultsO’Donnell, 2021 0.64 [0.35; 1.17] PlasmAr, 2020 1.40 [0.78; 2.51] REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46] Sekine (PLACOVID), 2021 1.14 [0.88; 1.48] 1.21[0.80; 1.83]O’Donnell, 2021, PlasmAr, 2020, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021463%2,692lownot evaluable adverse eventsdetailed resultsSekine (PLACOVID), 2021 1.08 [0.85; 1.38] 1.08[0.85; 1.38]Sekine (PLACOVID), 202110%160NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-03-28 17:47 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 538,957 - roots T: 290